Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum.
Giorgia SalviaMatteo BevilacquaFlavia Manzo MargiottaAlessandra MichelucciGiammarco GranieriCristian FidanziValentina DiniMarco RomanelliCarlo MazzatentaPublished in: The Australasian journal of dermatology (2024)